Out of the current antidiabetic medications, 2.4 mg semaglutide OW is the only one approved for the treatment of MASH by FDA Phase 3 trials with tirzepatide and dual GLP-1/glucagon agonist survodutide are ongoing Many other GLP-1-based emerging medications such as cagrilintide/semaglutide, triple GLP-1/GIP/glucagon agonist retatrutide, small non-peptide GLP-1 agonist orforglipron and many others may also have a great potential to improve MASLD or MASH Based on the excellent review paper by Scott Isaacs, MD, FACP, FACE and colleagues published in Frontline Gastroenterology #mash #mafld #antidiabeticmedication #semaglutide #tirzepatide #survodutide #pioglitazone #insulin #metformin #cvcomplications To view or add a comment, sign in Here's an excellent summary of role and benefits of anti-diabetic treatment options for the clinical management of MASH/MASLD
Glutathione-related enzymes in brain in Parkinson's disease
In late August 2015, the US FDA issued a warning that drugs like sitagliptin, saxagliptin, linagliptin, alogliptin, and other DPP-4 inhibitors could cause joint pain that can be severe and disabling
In conclusion, semaglutide represents a significant leap forward in the management of diabetes and obesity, offering hope for improved health outcomes and quality of life for millions of individuals around the globe
Reconstitution volume determines the final concentration of the solution, expressed as mass per volume (for example, mcg/mL)
Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling